The company announced in June that its partner Mundipharma has initiated the launch of Zubsolv (buprenorphine and naloxone sublingual tablet), for use in the treatment of opioid dependence, in the EU.
The launch is triggering a milestone payment of EUR 3 million (approx. SEK 30.6 million) from Mundipharma, reports the company.
“Taking the step out in Europe, is yet another important milestone for Orexo. There is a need for new and innovative treatments in light of such a serious health problem. Zubsolv will be an affordable and user-friendly treatment and the first therapy in Europe with a choice of up to six different strengths. This allows for finer titration and individualized dosing with potential for fewer tablets compared with existing treatments,” says Nikolaj Sørensen, President and CEO, Orexo AB, in the press release.
It is estimated that there are approximately 1.3 million high-risk opioid users in Europe. Although estimates vary significantly, the vast majority of high-risk opioid users use heroin.
Photo of Nikolaj Sørensen: Orexo AB
